Karyopharm Therapeutics | KPTI - صافي الدخل





صافي الدخل تغيير تاريخ
AbbVie USD 3.61B 2.92B 2026-06
Abbott USD 928M 149M 2026-06
Amgen USD 2.38B 556M 2026-06
AstraZeneca USD 2.51B 573M 2026-06
BioCryst Pharmaceuticals USD 78.4M 167.45M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Eli Lilly USD 7.1B 301M 2026-06
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
GlaxoSmithKline GBP 435M 1.3B 2026-06
Incyte USD 585.6M 282.27M 2026-06
J&J USD 5.53B 299M 2026-06
Karyopharm Therapeutics USD -22.39M 79.81M 2026-03
MacroGenics USD -36.77M 22.62M 2026-03
Merck USD -1.34B 2.9B 2026-06
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Novartis USD 3.26B 108M 2026-06
Novartis USD 3.16B 747M 2026-03
Pfizer USD -248M 2.94B 2026-06
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Roche Holding CHF 6.87B 1.4B 2026-06
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Takeda JPY 113.2B 137.52B 2026-06
Tectonic Therapeutic USD -25.24M 6.02M 2026-03
TG Therapeutics USD 7.78M 12M 2026-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Xencor USD -21.73M 107.19M 2026-06